To compare clinical outcomes of self-expanding nitinol stents and stainless steel stents after percutaneous peripheral intervention (PPI) for SFA CTO.
Between April 2004 and August 2007, a total of 25 SFA CTO lesions (nitinol stent group, 13; stainless steel stent group, 12) in 21 patients were treated with PPI, all patients were followed clinically, and 21 lesions (nitinol, 9; stainless steel, 12) received follow-up angiography. There was no significant difference in baseline characteristics, mean stent diameter (7.3 ± 0.7 mm vs. 6.9 ± 1.2 mm, p = 0.32), pre-ankle-brachial index (ABI), and Fontaine stage between groups. Mean occlusion length and stent length were significantly longer (129.5 ± 54.9 mm vs. 39.0 ± 20.6 mm, 250.8 ± 90.0 mm vs. 145.2 ± 64.6 mm, respectively, p < 0.01) and number of stents was significantly larger (2.8 ± 0.9 vs. 1.6 ± 0.5, p < 0.01) in the nitinol stent group. At follow-up, ABI was significantly lower (0.73 ± 0.20 vs. 0.95 ± 0.13, p = 0.04), restenosis rate and target lesion revascularization was significantly higher (58.3 % vs. 15.4 % , p = 0.03; 50.0 % vs. 7.7 % , p = 0.02, respectively) in the stainless steel stent group.
Our study demonstrates the superiority of nitinol stent implantation compared with stainless steel stent implantation for SFA CTO.